title: Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis.
abstract: OBJECTIVE
  Treatment of spontaneous bacterial peritonitis currently involves intravenous antibiotic administration. To test the possibility of treating spontaneous bacterial peritonitis with oral antibiotics, oral ofloxacin was compared with intravenous cefotaxime in this infection.
  
  
  METHODS
  One hundred twenty-three cirrhotics with uncomplicated spontaneous bacterial peritonitis (no septic shock, grade II-IV hepatic encephalopathy, serum creatinine level of > 3 mg/dL, and gastrointestinal hemorrhage or ileus) were randomly given oral ofloxacin (64 patients) or intravenous cefotaxime (59 patients).
  
  
  RESULTS
  Infection resolution rate was 84% in the ofloxacin group and 85% in the cefotaxime group. Peak serum levels and trough serum and ascitic fluid levels of ofloxacin and cefotaxime measured on days 3 (23 patients) and 6 (11 patients) of therapy were greater than the minimal inhibitory concentration of isolated organisms. Hospital survival rate was 81% in each group of patients. Blood urea nitrogen and hepatic encephalopathy at diagnosis were associated with prognosis. None of the 36 nonazotemic patients with community-acquired spontaneous bacterial peritonitis and without hepatic encephalopathy developed complications during hospitalization, and all were alive at time of discharge.
  
  
  CONCLUSIONS
  Oral ofloxacin is as effective as intravenous cefotaxime in uncomplicated spontaneous bacterial peritonitis. Nonazotemic cirrhotic patients with uncomplicated community-acquired spontaneous bacterial peritonitis and without hepatic encephalopathy have an excellent prognosis and may be treated with oral ofloxacin without requiring hospitalization.
authors.affiliation: Liver Unit, Hospital Clínic i Provincial, Barcelona, Spain.
authors.forename: M
authors.initials: M
authors.lastname: Navasa
authors.forename: A
authors.initials: A
authors.lastname: Follo
authors.forename: J M
authors.initials: JM
authors.lastname: Llovet
authors.forename: G
authors.initials: G
authors.lastname: Clemente
authors.forename: V
authors.initials: V
authors.lastname: Vargas
authors.forename: A
authors.initials: A
authors.lastname: Rimola
authors.forename: F
authors.initials: F
authors.lastname: Marco
authors.forename: C
authors.initials: C
authors.lastname: Guarner
authors.forename: M
authors.initials: M
authors.lastname: Forné
authors.forename: R
authors.initials: R
authors.lastname: Planas
authors.forename: R
authors.initials: R
authors.lastname: Bañares
authors.forename: L
authors.initials: L
authors.lastname: Castells
authors.forename: M T
authors.initials: MT
authors.lastname: Jimenez De Anta
authors.forename: V
authors.initials: V
authors.lastname: Arroyo
authors.forename: J
authors.initials: J
authors.lastname: Rodés
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000890:Anti-Infective Agents / Q000008:administration & dosage*; D001424:Bacterial Infections / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D002439:Cefotaxime / Q000008:administration & dosage* / Q000493:pharmacokinetics; D002511:Cephalosporins / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D015242:Ofloxacin / Q000008:administration & dosage* / Q000493:pharmacokinetics; D010538:Peritonitis / Q000150:complications / Q000188:drug therapy* / Q000401:mortality
chemical_list: D000890:Anti-Infective Agents; D002511:Cephalosporins; D015242:Ofloxacin; D002439:Cefotaxime